Biogen’s Zurzuvae Receives Positive CHMP Opinion for Postpartum Depression Treatment
US-based Biogen (NASDAQ: BIIB) announced that the Committee for Medicinal Products for Human Use (CHMP)...
NASDAQ: BIIB
Biogen’s Phase I Results Highlight Salanersen’s Potential in Spinal Muscular Atrophy
Biogen (NASDAQ: BIIB) announced this week topline results from the Phase I study of salanersen...
Biogen Launches Qalsody in China for SOD1-ALS Treatment
US-based Biogen (NASDAQ: BIIB) officially launched Qalsody (tofersen) in China this week. The drug, the...
Biogen and City Therapeutics Collaborate on RNAi Therapies for CNS Diseases
US-based Biogen Inc. (NASDAQ: BIIB) announced a strategic collaboration with compatriot firm City Therapeutics, Inc....
Biogen Reports 8% YOY Sales Growth in Q1 2025, Driven by Rare Disease Therapies
According to Biogen Inc.’s (NASDAQ: BIIB) Q1 2025 report released this week, the US firm...
Eisai and Biogen Win EU Approval for Leqembi in Early Alzheimer’s Disease
Eisai Co., Ltd. (TYO: 4523) and Biogen Inc. (NASDAQ: BIIB) jointly announced that they have...
TJ Biopharma Partners with Biogen on Felzartamab Phase III Studies in China
China-based TJ Biopharma has entered into an agreement with US-based Biogen Inc. (NASDAQ: BIIB) to...
Biogen’s BIIB080 Receives FDA Fast Track Designation for Alzheimer’s
US-based Biogen Inc. (NASDAQ: BIIB) announced that it has received Fast Track designation (FTD) from...
Organon Acquires U.S. Rights to TOFIDENCE from Biogen
Organon (NYSE: OGN) announced today that it has acquired regulatory and commercial rights in the...
Biogen Initiates TRANSCEND Study for Felzartamab in Late AMR Kidney Transplant Patients
US-based Biogen Inc. (NASDAQ: BIIB) announced the initiation of the TRANSCEND study, a global Phase...
Eisai’s Lecanemab Rejected by Australia’s TGA for Early Alzheimer’s Treatment
Japan-based Eisai Co., Ltd (TYO: 4523) announced that the Therapeutic Goods Administration (TGA) of Australia...
Biogen Licenses Stoke Therapeutics’ Zorevunersen for Dravet Syndrome Outside Americas
US-based Biogen Inc. (NASDAQ: BIIB) has entered into a licensing agreement with Stoke Therapeutics, Inc....
FDA Clears sBLA for Eisai and Biogen’s Leqembi Maintenance Dosing
Partners Eisai Co., Ltd (TYO: 4523) and Biogen Inc. (NASDAQ: BIIB) have announced that the...
Sinopharm Partners with Biogen for Comprehensive Service Agreement
China-based Sinopharm Group Co., Ltd (HKG: 1099) has entered into a strategic partnership with US-based...
Biogen Proposes to Acquire Sage Therapeutics for $469M
US-based Sage Therapeutics, Inc. (NASDAQ: SAGE) has announced that it received an unsolicited, nonbinding proposal...
Leqembi Autoinjector Advances with FDA Review for Alzheimer’s Treatment
Partners Eisai Co., Ltd (TYO: 4523) and Biogen Inc. (NASDAQ: BIIB) have announced that the...
Eisai and Biogen’s Leqembi Approved in Mexico for Early Alzheimer’s Disease Treatment
Eisai Co., Ltd (TYO: 4523) and Biogen Inc. (NASDAQ: BIIB) have announced that their co-developed...
Eisai and Biogen Launch Alzheimer’s Treatment Leqembi in South Korea
Partners Eisai Co., Ltd (TYO: 4523) and Biogen Inc. (NASDAQ: BIIB) have jointly announced the...
UCB and Biogen’s Dapirolizumab Pegol Shows Promise in Phase III SLE Study
Partners UCB (FRA: UNC) and Biogen Inc. (NASDAQ: BIIB) have announced positive results from a...
Biogen and Samsung Bioepis Win EC Approval for Opuviz Biosimilar in Europe
US-based Biogen Inc. (NASDAQ: BIIB) and South Korea’s Samsung Bioepis Co., Ltd. have jointly announced...